- Home
- HCC vs CPRX Comparison
HCC vs CPRX Comparison
Compare HCC & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- CPRX
- Stock Information
- Founded
- HCC 2015
- CPRX 2002
- Country
- HCC United States
- CPRX United States
- Employees
- HCC N/A
- CPRX N/A
- Industry
- HCC Coal Mining
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- CPRX Health Care
- Exchange
- HCC Nasdaq
- CPRX Nasdaq
- Market Cap
- HCC 2.8B
- CPRX 2.5B
- IPO Year
- HCC 2017
- CPRX 2006
- Fundamental
- Price
- HCC $56.04
- CPRX $22.78
- Analyst Decision
- HCC Buy
- CPRX Strong Buy
- Analyst Count
- HCC 6
- CPRX 7
- Target Price
- HCC $73.60
- CPRX $32.86
- AVG Volume (30 Days)
- HCC 734.4K
- CPRX 1.4M
- Earning Date
- HCC 02-12-2025
- CPRX 02-26-2025
- Dividend Yield
- HCC 0.57%
- CPRX N/A
- EPS Growth
- HCC N/A
- CPRX 114.68
- EPS
- HCC 7.26
- CPRX 1.18
- Revenue
- HCC $1,592,759,000.00
- CPRX $460,482,000.00
- Revenue This Year
- HCC N/A
- CPRX $23.98
- Revenue Next Year
- HCC $1.61
- CPRX $18.27
- P/E Ratio
- HCC $7.72
- CPRX $19.33
- Revenue Growth
- HCC N/A
- CPRX 32.17
- 52 Week Low
- HCC $49.97
- CPRX $13.12
- 52 Week High
- HCC $75.53
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- HCC 48.17
- CPRX 56.81
- Support Level
- HCC $49.97
- CPRX $21.23
- Resistance Level
- HCC $56.13
- CPRX $23.26
- Average True Range (ATR)
- HCC 2.05
- CPRX 1.14
- MACD
- HCC 0.63
- CPRX 0.20
- Stochastic Oscillator
- HCC 98.54
- CPRX 74.85
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.